Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 21, 2026.

The eEF1A Proteins: At the Crossroads of Oncogenesis, Apoptosis, and Viral Infections

Wasim Abbas, Amit Kumar, Georges Herbein

Frontiers in Oncology · 2015 · Review

doi:10.3389/fonc.2015.00075

Abstract

Eukaryotic translation elongation factors 1 alpha, eEF1A1 and eEF1A2, are not only translation factors but also pleiotropic proteins that are highly expressed in human tumors, including breast cancer, ovarian cancer, and lung cancer. eEF1A1 modulates cytoskeleton, exhibits chaperone-like activity and also controls cell proliferation and cell death. In contrast, eEF1A2 protein favors oncogenesis as shown by the fact that overexpression of eEF1A2 leads to cellular transformation and gives rise to tumors in nude mice. The eEF1A2 protein stimulates the phospholipid signaling and activates the Akt-dependent cell migration and actin remodeling that ultimately favors tumorigenesis. In contrast, inactivation of eEF1A proteins leads to immunodeficiency, neural and muscular defects, and favors apoptosis. Finally, eEF1A proteins interact with several viral proteins resulting in enhanced viral replication, decreased apoptosis, and increased cellular transformation. This review summarizes the recent findings on eEF1A proteins indicating that eEF1A proteins play a critical role in numerous human diseases through enhancement of oncogenesis, blockade of apoptosis, and increased viral pathogenesis.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 21, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Translation is the central event leading to protein synthesis and translation factors are key actors involved in the translation process. Recently, it has been suggested that translation factors could represent a new class of potential oncoproteins that could favor cellular transformation through protein translation infidelity, association with cytoskeleton alterations, and modulation of signaling pathways. The eukaryotic translation elongation factors 1 alpha, eEF1A1 and eEF1A2, are the second most abundant protein (1–3% of total protein content) after actin and an important component of translation machinery. In its GTP bound form, eEF1A1 and eEF1A2 deliver the aminoacylated-tRNA to the A site of the ribosome for decoding of mRNA by codon–anticodon interactions. Following the hydrolysis of GTP, eEF1A (eEF1A1 and eEF1A2), GDP is released from the ribosome. Thus, eEF1A1 and eEF1A2 are GTP-binding proteins and consist of three domains namely domain I, domain II, and domain III. Domain I spans over 1–240 residues, which made up of a Rossmann-fold topology. Domain II (241–336 amino acids) and domain III (residues 337–443) consist of beta strands and each domain contains two beta sheets that form the beta barrel (Figure 1).

There are two known isoforms of protein eEF1A, i.e., eEF1A1 and eEF1A2. The cellular expression of eEF1A is divided into three classes. First are the majority of cell types that express only eEF1A1. Second, neurons and muscle cells that express only eEF1A2. Third class belongs to certain tumor cell types and cell lines that express both eEF1A isoforms. eEF1A1 protein has been mapped on chromosomes 6q14. eEF1A1 protein shares homology with eEF1A2 protein at the nucleotide level (75%) and amino acid level (96%). eEF1A2 does not bind GDP and GTP with the same relative affinity as eEF1A1. The GDP dissociation rate constant is seven times higher for eEF1A1 than for eEF1A2. In addition, the nucleotide preference ratio (GDP/GTP) for eEF1A1 is 0.82 and for eEF1A2 is 1.50. Furthermore, eEF1A has been shown to be a novel component of the nuclear export machinery in mammalian cells and is involved in the nuclear export of specific proteins such as VHL van Hippel-Lindau (VHL) tumor suppressor and poly(A)-binding protein (PABP1).

The eEF1A2 gene is present in the common ancestor of eukaryotes (Table 1; Figure 2). Human eEF1A2 gene spans approximately 12 kb human genome sequence, which consists of eight exons and seven introns plus 2 kb upstream promoter region, and has been mapped on chromosome 20q13.3. Analysis of the region −2064 to +220 reveals that the promoter region contains the binding sites for several important cis-regulatory elements (E-boxes, EGR family proteins, GATA motif, and MEF binding site) with no TATA elements (Figure 3). The core region of the promoter is mapped from position −16 to +92. Beyond its central role in translation machinery, eEF1A2 plays an important role in cell cycle regulation, heat-shock response, aging, posttranslational modifications, and signal transduction.

Protein synthesis is one of the most sophisticated biochemical processes occurring in the cell, which requires hundred of proteins, including eEF1A proteins, eEF1A1 and eEF1A2. Besides the role of eEF1A proteins in the translational process, an increasing series of data are presently emerging about the non-canonical roles of these proteins in oncogenesis, modulation of apoptosis and viral pathogenesis.

Breast cancer

Breast cancer is the most common cancer in women both in the developing and developed world; there are an estimated 1 million new cases per year. The use of gene signature or the identification of changes in gene expression in breast tumors relative to normal surrounding tissue is of great importance in terms of prognostic indicators and therapeutic targets. The eEF1A2 is hardly detectable in normal human breast tissue but the expression of eEF1A2 is strongly upregulated in most of breast tumors. High levels of eEF1A2 proteins are detected in 60% of primary breast tumors and metastases, but not in normal epithelium (Table 2). The expression of eEF1A2 is sufficient to stimulate the formation of filopodia in BT549 human breast cancer cells and non-transformed Rat2 cells. Moreover, its expression is sufficient to activate Akt in a PI3K-dependent fashion, as down-regulation of eEF1A2 by siRNA reduces Akt activity. In breast cancer cell line BT549, eEF1A2 expression stimulates cell migration and invasion in a largely PI3K and Akt-dependent manner, suggesting eEF1A2 regulates oncogenesis through Akt and PI3K-dependent cytoskeleton remodeling. In fact, eEF1A2 participates in the regulation of the phospholipids signaling pathway (Figure 4). Phosphatidylinositols are negatively charged membrane bound phospholipids that participate in the pathways that regulate the cell proliferation, survival, cytoskeleton organization, vesicular trafficking, and oncogenesis. Phosphoinositols are composed of an inositol ring in which one or more −OH groups at the 3-, 4-, and 5-position of inositol ring are esterified with a phosphate group in all possible combinations. Specific kinase families (PI3K, PI4K, and PI5K) are responsible for phosphorylation at these sites. Overexpression of eEF1A2 protein up-regulates overall PI4K activity and cellular phosphatidylinositol 4-phosphate (PI4P) generation in human cells. Furthermore, eEF1A2 directly interacts with and activates phosphatidylinositol-4 kinase III β (a subfamily of PI4K), an enzyme that converts phosphatidylinositol to PI4P. Knockdown of eEF1A2 using eEF1A2 siRNA results in down-regulation of phosphatidylinositol-4-kinase activity indicating that eEF1A2 is a physiological regulator of PI4KIIIβ signaling. In addition, eEF1A2 expression up-regulates the generation of phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2] in the cytoplasm and at the plasma membrane. The subsequent increase in PI(4,5)P2 at the plasma membrane stimulates the eEF1A2-induced filopodia formation through binding and activation of PI4KIII β. Therefore, eEF1A2 is involved in phosphatidylinositol signaling and actin remodeling. Moreover, the gene expression profiling of primary mouse B cell lineage showed the high expression of eEF1A2 in plasmacytomas (PCT), which results in progression of plasma cell neoplasms in both mouse and human. Finally, the knockdown of eEF1A2 expression delays or impairs the IL-6-induced activation of STAT3 and Akt signaling pathways suggesting that activation of STAT3 and Akt through eEF1A2 involvement that favors cell proliferation, cell cycle progression, and inhibition of apoptosis. Altogether, eEF1A2 protein activates the PIK-Akt-STAT3 pathways that have been extensively shown to favor cellular transformation and oncogenesis (Figure 4).

In breast cancer, the genes in 20q13 are frequently amplified and have been shown by using comparative genomic hybridization and fluorescence in situ hybridization. The differential screening of cDNA libraries from metastatic and non-metastatic cell lines derived from the same parental rat mammary adenocarcinoma showed a 1.5-fold overexpression of eEF1A in the metastatic compared to the non-metastatic cells. Studying cancer cell lines derived from breast, lung, prostate, and skin, eEF1A2 gene expression exhibited the highest alteration in the cancer cell lines compared to normal controls using a profiling array.

Ovarian cancer

Ovarian cancer represents 4% of all female cancer. It has the highest fatality to case ratio of all gynecological cancers because the majority of cases are diagnosed in the late stage. Despite of significant efforts to improve the early detection and advances in chemotherapy, metastasis remains a major challenge in clinical management of ovarian cancer. The eEF1A2 gene is not expressed in normal ovary but highly expressed in ovarian cancer. eEF1A2 expression enhances the ovarian cell growth in vitro and favors the tumorsphere formation, suggesting that eEF1A2 could favor the development of ovarian primary tumor formation. High levels of eEF1A2 expression was observed in 30% all the primary ovarian tumors, 50% of serous tumors, 30% of endometrioid tumors, 19% of mucinous tumors, and 8% of clear-cell tumors (Table 2). Furthermore, the eEF1A2 protein and RNA expression levels are upregulated in clear-cell ovarian carcinoma by 75 and 33% respectively. The eEF1A2 gene is unmethylated both in normal and tumor cells, suggesting that up-regulation of eEF1A2 gene expression is not dependent on epigenetic modifications (at least for the methylation status), but instead that the inappropriate expression of trans-acting factor(s) could be involved. The enhanced expression of eEF1A2 protein in ovarian cancers correlates with poor prognosis.

The oncogenic properties of eEF1A2 have also been studied in different ovarian tumors and established cell lines. In rodent fibroblasts, eEF1A2 protein favors anchorage-independent growth and results in decreased doubling time during cellular proliferation. Furthermore, the induced expression of eEF1A2 in NIH3T3 cells makes them tumorigenic and increases the growth rate of ES-2 ovarian carcinoma cells xenografted in nude mice. The transcription factor ZNF217 and eEF1A2, both located on chromosome 20q13, are frequently amplified in ovarian epithelial carcinomas. The stable preneoplastic ovarian cell lines that over-express eEF1A2 provides the evidence that up-regulation of eEF1A2 expression contributes to the neoplastic properties of precursor cells of ovarian carcinomas mediated through ZNF217.

Resveratrol, a phytoalexin produced naturally by several fruit plants, has been extensively studied for its chemopreventive and chemotherapeutic effects in cancer and animal models. Resveratrol blocks the angiogenesis, induces the autophagocytosis and apoptosis in proliferating cells, and is a well-known sirtuin 1 activator. The expression of eEF1A2 is increased in the PA-1 ovarian cell line after serum or insulin stimulation. Resveratrol up-regulates the caspase-3 level in PA-1 cells by down regulating the expression of eEF1A2 via the blockade of upstream Akt pathway. Additionally, resveratrol suppresses growth of human ovarian cancer cells in culture and in a murine xenograft model with reduced expression of proliferating cell nuclear antigen and increased TUNEL staining. All together resveratrol down-regulates eEF1A2 in ovarian cancer cells and thereby favors apoptosis.

Lung cancer

Lung cancer is the most common cause of cancer related death both in men and women. It accounts for 1.3 million deaths worldwide annually. In spite of continuous efforts and clinical trials to develop new diagnostic and prognostic markers, a better understanding of the molecular pathways involved in lung cancer is essential for developing new therapeutic targets. Four lung adenocarcinoma cell lines (HKULC 1–4) were established from patients with different clinical characteristics. Comprehensive studies of these cell lines show that eEF1A2 is a putative oncogene that is highly expressed in all the HKULC cell lines. In addition, high-resolution analysis of genomic aberration by metaphase and comparative genomic hybridization array identify the involvement of the 20q region, suggesting the potential role of eEF1A2 as a candidate tumor gene in lung cancer cell lines. In another study, 183 genes with increment in both genomic copy number and transcript in six lung adenocarcinoma were analyzed. Forty-two proteins were overexpressed in these cell lines as compared to the normal cells. Comparing the 183 genes with the 42 proteins, the expression of four candidates, namely, PRDX1, eEF1A2, CALR, and KCIP-1 was correlated with increased DNA copy number and transcript levels. Furthermore, expression of siRNA targeting eEF1A2 and KCIP-1 in these cell lines suppressed cellular proliferation and triggered apoptosis. Therefore, the overexpression of eEF1A2 and KCIP-1 in lung tumor samples strongly suggests that both proteins could be involved in lung adenocarcinoma and could be potential therapeutic targets in lung cancer.

Liver cancer

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in humans. HCC cell lines, HepG2, HuH7, and JHH6 show increased expression of eEF1A2 as compare to normal liver tissue, but the mRNA of eEF1A2 is markedly increased only in JHH6 cells. In addition, the MDM4 and eEF1A2 proteins show increased expression in cryptogenic HCC. eEF1A2 gene silencing reduces cell viability, proliferation, and increases the apoptosis rates in HCC cell lines. Furthermore, eEF1A2 is overexpressed in 43% of HCC and activates the Akt pathway as observed in 40–60% of primary HCCs (Table 2). Using array based comparative genomic hybridization, frequent amplification and gain of DNA copy number at 1q, 6p, 8q, 17q, and 20q were observed in HCCs, suggesting that these genetic aberrations might facilitate the malignant transformation.

Pancreatic cancer

Pancreatic cancer is one of the unsolved health problems associated with aggressive malignancies and therefore there is need to develop improved early diagnosis tools. The expression of eEF1A2 gene, located on chromosome 20q13 is significantly upregulated in pancreatic cancer. Although little or no eEF1A2 expression is present in normal pancreatic tissue, 83% of pancreatic cancers display increased expression of eEF1A2, suggesting that eEF1A2 plays an important role in pancreatic carcinogenesis.

Apoptosis

Cell proliferation and cell death are highly regulated and coordinated during the normal development, and both are crucial for the maintenance of tissue homeostasis. Impaired apoptosis can lead to autoimmunity or malignancy. An increasing number of evidence suggests the involvement of eEF1A2 at the onset of cell transformation. Peroxiredoxin-1 (Prx-1) is a protein that is ubiquitously expressed in all mammalian cells and protects the cells from oxidative stress by reducing the range of reactive oxygen species. eEF1A2 interacts directly with Prx-1 and protects the cells from stress-induced apoptosis by the down-regulation of caspase-3 and caspase-8 activation parallel to increased expression of the pro-survival factor Akt. Additionally, the eEF1A expression varies in cells treated with various concentrations of hydrogen peroxide, a strong apoptotic inducer associated with decreased mitochondrial respiration and an inhibitor of Prx-1. Finally, eEF1A provides protection against all endoplasmic reticulum (ER) stress-mediated cell death. FL5.12 cells are non-transformed murine B-cells that require IL-3 for growth, survival, and proliferation. Enforced expression of eEF1A in these cells protects them from IL-3 withdrawal without cellular transformation.

Wasted mouse is a spontaneous autosomal recessive mutation associated with neurological defects, immune system abnormalities, and defective response to DNA damage repair in immune cells. Thymus and spleen from wasted mice show extensive apoptosis. The loss of activity in wasted mice and immunological abnormalities are solely linked to the presence of a deletion in the eef1a2 gene. Furthermore, eEF1A2 is highly expressed in terminally differentiated cells such as neurons, cardiomyocytes, and myofibers. During skeletal muscle development, undifferentiated myoblasts are susceptible to serum deprived caspase 3-mediated apoptosis but become resistant to apoptosis after differentiating into myotubes. In muscle cells, the eEF1A1 is expressed during embryonic development of myoblast but is replaced by eEF1A2 after 2 weeks of birth indicating that the eEF1A1 isoform plays a pro-apoptotic role while the eEF1A2 isoform displays anti-apoptotic properties.

Viral Infections

The eEF1A proteins play a critical role in several viral infections at distinct stages of the viral cycle [reviewed in Ref.] (Table 3). Among the most studied viruses, human immunodeficiency virus (HIV) interacts with numerous cellular proteins, including eEF1A. First, eEF1A has been detected as part of the HIV virions as an actin-binding protein. Second, eEF1A has been reported to plays a critical role at early stages of HIV replication (Figure 5). eEF1A and also EF1G are part of HIV reverse transcription complex (RTC). Both eEF1A and EF1G proteins coimmunoprecipitated with the p51 subunit of reverse transcriptase (RT) and integrase using an endogenous reverse transcription assay (Figure 5). The depletion of eEF1A and EF1G using siRNAs decreased reverse transcription parallel to reduced levels of RTC in treated cells. Since integrase is also an RT binding protein, a tight interplay between RT, integrase, and eEF1A could be involved in several stages of HIV replication. Actually, integrase has been shown to interact with eEF1A in vitro. eEF1A also interacts with other viral proteins involved in early stages of HIV replication such as Nef and Tat. Several reports indicate that HIV Nef interacts with eEF1A (Figure 5). Abbas and colleagues have shown that the Nef-eEF1A interaction favors the nucleo-cytoplasmic shuttling of eEF1A and ultimately inhibits stress-mediated apoptosis in monocyte-derived macrophages. Additionally, Nef interaction with actin impairs human podocyte actin cytoskeletal integrity and eEF1A could play a role in the development of podocyte phenotype in HIV-1 associated nephropathy. The trans-activation response (TAR) element is critical for the activation of HIV-1 transcription. eEF1A stimulates the RNA polymerase II and TRP-185 binding to TAR RNA, which in turn regulates the HIV-1 gene expression. eEF1A has been described to interact with the HIV Gag protein. Finally, eEF1A is responsible for the selection and binding of cognate aminoacyl-tRNAs to the A site of the ribosome. HIV Nef interacts with two components of the 40S small ribosomal subunit, the RPS10 protein, and the 18S rRNA, and also to tRNAs, and has been reported to decrease translation using an in vitro translation assay. We cannot exclude that eEF1A that binds to both Nef and tRNA participates in the control of translation in HIV-infected cells. Interestingly, EF1-delta has been reported to interact with the second coding exon of HIV Tat, and to result in reduced efficiency of the translation of cellular proteins, but not of viral mRNAs.

Since overexpression of eEF1A has been reported in several cancers, we cannot exclude a link between oncoviruses and eEF1A. Among oncoviruses, hepatitis B virus expresses the HBx protein that has been previously involved in liver cancer, especially HCC. HBx protein has been reported to interact with eEF1A1 in Huh-7 hepatoma cells infected with recombinant adenovirus expressing HBx protein. Interaction of HBx protein with eEF1A1 blocks filamentous actin bundling. Interestingly, the hepatitis delta virus (HDV) that can propagate only in the presence of HBV has a RNA genome that also interacts with eEF1A1. A dozen of human papillomavirus (HPV) types including HPV16 and HPV18 are well-known oncoviruses that express two oncoproteins E6 and E7, and favor cellular transformation, oncogenesis, and the appearance of cervical cancers. E7 protein of HPV38 has been shown to interact with both eEF1A1 and eEF1A2 proteins leading to cellular immortalization and transformation of primary keratinocytes probably through disruption of actin stress fiber formation, a critical event linked to tumor formation. eEF1A facilitates virus replication complex (RPC) assembly and favors replication of West Nile virus and dengue virus. Similarly, eEF1A interacts with the nucleocapsid protein of transmissible gastroenteritis coronavirus (TGEV) and favors TGEV replication. Since eEF1A is found in highly purified virions of numerous RNA and DNA viruses including vesicular stomatitis virus, vaccinia virus, cytomegalovirus, severe acute respiratory syndrome coronavirus (SARS-CoV), and HIV-1, its role in viral pathogenesis needs to be further investigated.

Conclusion

Recent findings in the field of cellular and molecular biology reveal that the eEF1A proteins are not only involved in the translational process but display also non-canonical functions. The specific up-regulation of eEF1A2 in numerous tumors and its transforming properties indicate that it could play a significant role in tumorigenesis. Furthermore, eEF1A2 activates the phospholipid and Akt signaling pathways favoring cell survival. Additionally, eEF1A proteins block apoptosis and favors viral replication. All together, the non-canonical functions of eEF1A proteins are involved at the crossroads of oncogenesis, blockade of apoptosis, and viral pathogenesis. Therefore, the eEF1A proteins might play an important role in the pathophysiology of tumors and apoptosis, especially in response to stress and viral infections. Future studies need to be done to further highlight the role of eEF1A proteins in human diseases.

Author Contributions

WA and AK were responsible for drafting and revising the manuscript. GH was involved in critical reading of the manuscript.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 112

  1. 1.

    Thornton S Anand N Purcell D Lee J. Not just for housekeeping: protein initiation and elongation factors in cell growth and tumorigenesis. J Mol Med (Berl) (2003 ) 81(9):536–48.

    Not in our library10.1007/s00109-003-0461-8

  2. 2.

    Li GW Xie XS. Central dogma at the single-molecule level in living cells. Nature (2011 ) 475(7356):308–15.

    Not in our library10.1038/nature10315

  3. 3.

    Garner AL Janda KD. Protein-protein interactions and cancer: targeting the central dogma. Curr Top Med Chem (2011 ) 11(3):258–80.

    Not in our library10.2174/156802611794072614

  4. 4.

    Caraglia M Budillon A Vitale G Lupoli G Tagliaferri P Abbruzzese A. Modulation of molecular mechanisms involved in protein synthesis machinery as a new tool for the control of cell proliferation. Eur J Biochem (2000 ) 267(13):3919–36.

    Not in our library10.1046/j.1432-1327.2000.01465.x

  5. 5.

    Clemens MJ. Targets and mechanisms for the regulation of translation in malignant transformation. Oncogene (2004 ) 23(18):3180–8.

    Not in our library10.1038/sj.onc.1207544

  6. 6.

    Browne GJ Proud CG. Regulation of peptide-chain elongation in mammalian cells. Eur J Biochem (2002 ) 269(22):5360–8.

    Not in our library10.1046/j.1432-1033.2002.03290.x

  7. 7.

    Soares DC Barlow PN Newbery HJ Porteous DJ Abbott CM. Structural models of human eEF1A1 and eEF1A2 reveal two distinct surface clusters of sequence variation and potential differences in phosphorylation. PLoS One (2009 ) 4(7):e6315.

    Not in our library10.1371/journal.pone.0006315

  8. 8.

    Panwar D Rawal L Ali S. Molecular docking uncovers TSPY binds more efficiently with eEF1A2 compared to eEF1A1. J Biomol Struct Dyn (2014 ) 9:1–12.

    Not in our library10.1080/07391102.2014.952664

  9. 9.

    Yaremchuk A Shalak VF Novosylna OV Negrutskii BS Crepin T El’skaya AV Purification, crystallization and preliminary X-ray crystallographic analysis of mammalian translation elongation factor eEF1A2. Acta Crystallogr Sect F Struct Biol Cryst Commun (2012 ) 68(Pt 3):295–7.

    Not in our library10.1107/s1744309112000243

  10. 10.

    Schwede T Kopp J Guex N Peitsch MC. SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Res (2003 ) 31(13):3381–5.

    Not in our library10.1093/nar/gkg520

  11. 11.

    Knudsen SM Frydenberg J Clark BF Leffers H. Tissue-dependent variation in the expression of elongation factor-1 alpha isoforms: isolation and characterisation of a cDNA encoding a novel variant of human elongation-factor 1 alpha. Eur J Biochem (1993 ) 215(3):549–54.

    Not in our library10.1111/j.1432-1033.1993.tb18064.x

  12. 12.

    Sasikumar AN Perez WB Kinzy TG. The many roles of the eukaryotic elongation factor 1 complex. Wiley Interdiscip Rev RNA. (2012 ) 3(4):543–55.

    Not in our library10.1002/wrna.1118

  13. 13.

    Doig J Griffiths LA Peberdy D Dharmasaroja P Vera M Davies FJ In vivo characterization of the role of tissue-specific translation elongation factor 1A2 in protein synthesis reveals insights into muscle atrophy. FEBS J (2013 ) 280(24):6528–40.

    Not in our library10.1111/febs.12554

  14. 14.

    Kahns S Lund A Kristensen P Knudsen CR Clark BF Cavallius J The elongation factor 1 A-2 isoform from rabbit: cloning of the cDNA and characterization of the protein. Nucleic Acids Res (1998 ) 26(8):1884–90.

    Not in our library10.1093/nar/26.8.1884

  15. 15.

    Lund A Knudsen SM Vissing H Clark B Tommerup N. Assignment of human elongation factor 1alpha genes: eEF1A maps to chromosome 6q14 and eEF1A2 to 20q13.3. Genomics (1996 ) 36(2):359–61.

    Not in our library10.1006/geno.1996.0475

  16. 16.

    Soares DC Abbott CM. Highly homologous eEF1A1 and eEF1A2 exhibit differential post-translational modification with significant enrichment around localised sites of sequence variation. Biol Direct (2013 ) 8:29.

    Not in our library10.1186/1745-6150-8-29

  17. 17.

    Sanges C Scheuermann C Zahedi RP Sickmann A Lamberti A Migliaccio N Raf kinases mediate the phosphorylation of eukaryotic translation elongation factor 1A and regulate its stability in eukaryotic cells. Cell Death Dis (2012 ) 3:e276.

    Not in our library10.1038/cddis.2012.16

  18. 18.

    Khacho M Mekhail K Pilon-Larose K Pause A Cote J Lee S. eEF1A is a novel component of the mammalian nuclear protein export machinery. Mol Biol Cell (2008 ) 19(12):5296–308.

    Not in our library10.1091/mbc.e08-06-0562

  19. 19.

    Bischoff C Kahns S Lund A Jorgensen HF Praestegaard M Clark BF The human elongation factor 1 A-2 gene (EEF1A2): complete sequence and characterization of gene structure and promoter activity. Genomics (2000 ) 68(1):63–70.

    Not in our library10.1006/geno.2000.6271

  20. 20.

    Lamberti A Caraglia M Longo O Marra M Abbruzzese A Arcari P. The translation elongation factor 1A in tumorigenesis, signal transduction and apoptosis: review article. Amino Acids (2004 ) 26(4):443–8.

    Not in our library10.1007/s00726-004-0088-2

  21. 21.

    Gandin V Gutierrez GJ Brill LM Varsano T Feng Y Aza-Blanc P Degradation of newly synthesized polypeptides by ribosome-associated RACK1/c-Jun N-terminal kinase/eukaryotic elongation factor 1A2 complex. Mol Cell Biol (2013 ) 33(13):2510–26.

    Not in our library10.1128/mcb.01362-12

  22. 22.

    Veeramah KR Johnstone L Karafet TM Wolf D Sprissler R Salogiannis J Exome sequencing reveals new causal mutations in children with epileptic encephalopathies. Epilepsia (2013 ) 54(7):1270–81.

    Not in our library10.1111/epi.12201

  23. 23.

    Miura P Coriati A Belanger G De RY Lee J Kothary R The utrophin A 5’-UTR drives cap-independent translation exclusively in skeletal muscles of transgenic mice and interacts with eEF1A2. Hum Mol Genet (2010 ) 19(7):1211–20.

    Not in our library10.1093/hmg/ddp591

  24. 24.

    Hinestrosa MC Dickersin K Klein P Mayer M Noss K Slamon D Shaping the future of biomarker research in breast cancer to ensure clinical relevance. Nat Rev Cancer (2007 ) 7(4):309–15.

    Not in our library10.1038/nrc2144

  25. 25.

    Tomlinson VA Newbery HJ Wray NR Jackson J Larionov A Miller WR Translation elongation factor eEF1A2 is a potential oncoprotein that is overexpressed in two-thirds of breast tumours. BMC Cancer (2005 ) 5:113.

    Not in our library10.1186/1471-2407-5-113

  26. 26.

    Yao N Chen CY Wu CY Motonishi K Kung HJ Lam KS. Novel flavonoids with antiproliferative activities against breast cancer cells. J Med Chem (2011 ) 54(13):4339–49.

    Not in our library10.1021/jm101440r

  27. 27.

    Amiri A Noei F Jeganathan S Kulkarni G Pinke DE Lee JM. eEF1A2 activates Akt and stimulates Akt-dependent actin remodeling, invasion and migration. Oncogene (2007 ) 26(21):3027–40.

    Not in our library10.1038/sj.onc.1210101

  28. 28.

    Pecorari L Marin O Silvestri C Candini O Rossi E Guerzoni C Elongation factor 1 alpha interacts with phospho-Akt in breast cancer cells and regulates their proliferation, survival and motility. Mol Cancer (2009 ) 8:58.

    Not in our library10.1186/1476-4598-8-58

  29. 29.
    Eef1a2 promotes cell growth, inhibits apoptosis and activates JAK/STAT and AKT signaling in mouse plasmacytomas. · 2010
    Not checked
  30. 30.

    Fruman DA Meyers RE Cantley LC. Phosphoinositide kinases. Annu Rev Biochem (1998 ) 67:481–507.

    Not in our library10.1146/annurev.biochem.67.1.481

  31. 31.

    Bunney TD Katan M. Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nat Rev Cancer (2010 ) 10(5):342–52.

    Not in our library10.1038/nrc2842

  32. 32.

    Balla A Balla T. Phosphatidylinositol 4-kinases: old enzymes with emerging functions. Trends Cell Biol (2006 ) 16(7):351–61.

    Not in our library10.1016/j.tcb.2006.05.003

  33. 33.

    Carpenter CL Cantley LC. Phosphoinositide kinases. Curr Opin Cell Biol (1996 ) 8(2):153–8.

    Not in our library10.1016/s0955-0674(96)80060-3

  34. 34.

    Jeganathan S Lee JM. Binding of elongation factor eEF1A2 to phosphatidylinositol 4-kinase beta stimulates lipid kinase activity and phosphatidylinositol 4-phosphate generation. J Biol Chem (2007 ) 282(1):372–80.

    Not in our library10.1074/jbc.m602955200

  35. 35.

    Pinke DE Lee JM. The lipid kinase PI4KIIIbeta and the eEF1A2 oncogene co-operate to disrupt three-dimensional in vitro acinar morphogenesis. Exp Cell Res (2011 ) 317(17):2503–11.

    Not in our library10.1016/j.yexcr.2011.08.002

  36. 36.

    Jeganathan S Morrow A Amiri A Lee JM. Eukaryotic elongation factor 1A2 cooperates with phosphatidylinositol-4 kinase III beta to stimulate production of filopodia through increased phosphatidylinositol-4,5 bisphosphate generation. Mol Cell Biol (2008 ) 28(14):4549–61.

    Not in our library10.1128/mcb.00150-08

  37. 37.

    Vislovukh A Kratassiouk G Porto E Gralievska N Beldiman C Pinna G Proto-oncogenic isoform A2 of eukaryotic translation elongation factor eEF1 is a target of miR-663 and miR-744. Br J Cancer (2013 ) 108(11):2304–11.

    Not in our library10.1038/bjc.2013.243

  38. 38.

    Lee MH Choi BY Cho YY Lee SY Huang Z Kundu JK Tumor suppressor p16(INK4a) inhibits cancer cell growth by downregulating eEF1A2 through a direct interaction. J Cell Sci (2013 ) 126(Pt 8):1744–52.

    Not in our library10.1242/jcs.113613

  39. 39.

    Kulkarni G Turbin DA Amiri A Jeganathan S Andrade-Navarro MA Wu TD Expression of protein elongation factor eEF1A2 predicts favorable outcome in breast cancer. Breast Cancer Res Treat (2007 ) 102(1):31–41.

    Not in our library10.1007/s10549-006-9315-8

  40. 40.

    Anand N Murthy S Amann G Wernick M Porter LA Cukier IH Protein elongation factor eEF1A2 is a putative oncogene in ovarian cancer. Nat Genet (2002 ) 31(3):301–5.

    Not in our library10.1038/ng904

  41. 41.

    Zhu H Lam DC Han KC Tin VP Suen WS Wang E High resolution analysis of genomic aberrations by metaphase and array comparative genomic hybridization identifies candidate tumour genes in lung cancer cell lines. Cancer Lett (2007 ) 245(1–2):303–14.

    Not in our library10.1016/j.canlet.2006.01.020

  42. 42.

    Li R Wang H Bekele BN Yin Z Caraway NP Katz RL Identification of putative oncogenes in lung adenocarcinoma by a comprehensive functional genomic approach. Oncogene (2006 ) 25(18):2628–35.

    Not in our library10.1038/sj.onc.1209289

  43. 43.

    Grassi G Scaggiante B Farra R Dapas B Agostini F Baiz D The expression levels of the translational factors eEF1A 1/2 correlate with cell growth but not apoptosis in hepatocellular carcinoma cell lines with different differentiation grade. Biochimie (2007 ) 89(12):1544–52.

    Not in our library10.1016/j.biochi.2007.07.007

  44. 44.

    Schlaeger C Longerich T Schiller C Bewerunge P Mehrabi A Toedt G Etiology-dependent molecular mechanisms in human hepatocarcinogenesis. Hepatology (2008 ) 47(2):511–20.

    Not in our library10.1002/hep.22033

  45. 45.

    Tanner MM Tirkkonen M Kallioniemi A Holli K Collins C Kowbel D Amplification of chromosomal region 20q13 in invasive breast cancer: prognostic implications. Clin Cancer Res (1995 ) 1(12):1455–61.

    Not in our library

  46. 46.

    Edmonds BT Wyckoff J Yeung YG Wang Y Stanley ER Jones J Elongation factor-1 alpha is an overexpressed actin binding protein in metastatic rat mammary adenocarcinoma. J Cell Sci (1996 ) 109(Pt 11):2705–14.

    Not in our library10.1242/jcs.109.11.2705

  47. 47.

    Joseph P O’Kernick CM Othumpangat S Lei YX Yuan BZ Ong TM. Expression profile of eukaryotic translation factors in human cancer tissues and cell lines. Mol Carcinog (2004 ) 40(3):171–9.

    Not in our library10.1002/mc.20033

  48. 48.

    Sun Y Du C Wang B Zhang Y Liu X Ren G. Up-regulation of eEF1A2 promotes proliferation and inhibits apoptosis in prostate cancer. Biochem Biophys Res Commun (2014 ) 450(1):1–6.

    Not in our library10.1016/j.bbrc.2014.05.045

  49. 49.
    iTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancer. · 2012
    Not checked
  50. 50.

    Tatsuka M Mitsui H Wada M Nagata A Nojima H Okayama H. Elongation factor-1 alpha gene determines susceptibility to transformation. Nature (1992 ) 359(6393):333–6.

    Not in our library10.1038/359333a0

  51. 51.

    Agarwal R Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer (2003 ) 3(7):502–16.

    Not in our library10.1038/nrc1123

  52. 52.

    Naora H Montell DJ. Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer (2005 ) 5(5):355–66.

    Not in our library10.1038/nrc1611

  53. 53.

    Hennessy BT Coleman RL Markman M Ovarian cancer. Lancet (2009 ) 374(9698):1371–82

    Not in our library10.1016/s0140-6736(09)61338-6

  54. 54.
    Therapeutic strategies in epithelial ovarian cancer · 2012
    No notice
  55. 55.

    Tomlinson VA Newbery HJ Bergmann JH Boyd J Scott D Wray NR Expression of eEF1A2 is associated with clear cell histology in ovarian carcinomas: overexpression of the gene is not dependent on modifications at the eEF1A2 locus. Br J Cancer (2007 ) 96(10):1613–20.

    Not in our library10.1038/sj.bjc.6603748

  56. 56.

    Pinke DE Kalloger SE Francetic T Huntsman DG Lee JM. The prognostic significance of elongation factor eEF1A2 in ovarian cancer. Gynecol Oncol (2008 ) 108(3):561–8.

    Not in our library10.1016/j.ygyno.2007.11.019

  57. 57.

    Lee MH Surh YJ eEF1A2 as a putative oncogene. Ann N Y Acad Sci (2009 ) 1171:87–93

    Not in our library10.1111/j.1749-6632.2009.04909.x

  58. 58.

    Sun Y Wong N Guan Y Salamanca CM Cheng JC Lee JM The eukaryotic translation elongation factor eEF1A2 induces neoplastic properties and mediates tumorigenic effects of ZNF217 in precursor cells of human ovarian carcinomas. Int J Cancer (2008 ) 123(8):1761–9.

    Not in our library10.1002/ijc.23708

  59. 59.

    Kundu JK Surh YJ. Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett (2008 ) 269(2):243–61.

    Not in our library10.1016/j.canlet.2008.03.057

  60. 60.

    Wendling D Abbas W Godfrin-Valnet M Guillot X Khan KA Cedoz JP Resveratrol, a sirtuin 1 activator, increases IL-6 production by peripheral blood mononuclear cells of patients with knee osteoarthritis. Clin Epigenetics (2013 ) 5(1):10.

    Not in our library10.1186/1868-7083-5-10

  61. 61.

    Lee MH Choi BY Kundu JK Shin YK Na HK Surh YJ. Resveratrol suppresses growth of human ovarian cancer cells in culture and in a murine xenograft model: eukaryotic elongation factor 1A2 as a potential target. Cancer Res (2009 ) 69(18):7449–58.

    Not in our library10.1158/0008-5472.can-09-1266

  62. 62.

    Jemal A Siegel R Xu J Ward E Cancer statistics, 2010. CA Cancer J Clin (2010 ) 60(5):277–300

    Not in our library10.3322/caac.20073

  63. 63.

    Marugame T Hirabayashi Y Comparison of time trends in lung cancer mortality (1990-2006) in the world, from the WHO mortality database. Jpn J Clin Oncol (2009 ) 39(10):696–7

    Not in our library10.1093/jjco/hyp138

  64. 64.

    Lam DC Girard L Suen WS Chung LP Tin VP Lam WK Establishment and expression profiling of new lung cancer cell lines from Chinese smokers and lifetime never-smokers. J Thorac Oncol (2006 ) 1(9):932–42.

    Not in our library10.1097/01243894-200611000-00003

  65. 65.

    Effendi K Sakamoto M Molecular pathology in early hepatocarcinogenesis. Oncology (2010 ) 78(2):157–60

    Not in our library10.1159/000312658

  66. 66.

    Ayyappan AP Jhaveri KS. CT and MRI of hepatocellular carcinoma: an update. Expert Rev Anticancer Ther (2010 ) 10(4):507–19.

    Not in our library10.1586/era.10.24

  67. 67.

    Pellegrino R Calvisi DF Neumann O Kolluru V Wesely J Chen X eEF1A2 inactivates p53 by way of PI3K/AKT/mTOR-dependent stabilization of MDM4 in hepatocellular carcinoma. Hepatology (2014 ) 59(5):1886–99.

    Not in our library10.1002/hep.26954

  68. 68.

    Farazi PA DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer (2006 ) 6(9):674–87.

    Not in our library10.1038/nrc1934

  69. 69.

    Li D Xie K Wolff R Abbruzzese JL. Pancreatic cancer. Lancet (2004 ) 363(9414):1049–57.

    Not in our library10.1016/s0140-6736(04)15841-8

  70. 70.

    Shaib YH Davila JA El-Serag HB. The epidemiology of pancreatic cancer in the United States: changes below the surface. Aliment Pharmacol Ther (2006 ) 24(1):87–94.

    Not in our library10.1111/j.1365-2036.2006.02961.x

  71. 71.

    Cao H Zhu Q Huang J Li B Zhang S Yao W Regulation and functional role of eEF1A2 in pancreatic carcinoma. Biochem Biophys Res Commun (2009 ) 380(1):11–6.

    Not in our library10.1016/j.bbrc.2008.12.171

  72. 72.

    Xu C Hu DM Zhu Q. eEF1A2 promotes cell migration, invasion and metastasis in pancreatic cancer by upregulating MMP-9 expression through Akt activation. Clin Exp Metastasis (2013 ) 30(7):933–44.

    Not in our library10.1007/s10585-013-9593-6

  73. 73.

    Duanmin H Chao X Qi Z. eEF1A2 protein expression correlates with lymph node metastasis and decreased survival in pancreatic ductal adenocarcinoma. Hepatogastroenterology (2013 ) 60(124):870–5.

    Not in our library10.5754/hge12869

  74. 74.

    Fan Y Bergmann A. Apoptosis-induced compensatory proliferation. The cell is dead. Long live the cell! Trends Cell Biol (2008 ) 18(10):467–73.

    Not in our library10.1016/j.tcb.2008.08.001

  75. 75.

    Adams JM Cory S. Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr Opin Immunol (2007 ) 19(5):488–96.

    Not in our library10.1016/j.coi.2007.05.004

  76. 76.

    Chang R Wang E. Mouse translation elongation factor eEF1A-2 interacts with Prdx-I to protect cells against apoptotic death induced by oxidative stress. J Cell Biochem (2007 ) 100(2):267–78.

    Not in our library10.1002/jcb.20969

  77. 77.

    Abbas W Khan KA Kumar A Tripathy MK Dichamp I Keita M Blockade of BFA-mediated apoptosis in macrophages by the HIV-1 Nef protein. Cell Death Dis (2014 ) 5:e1080.

    Not in our library10.1038/cddis.2014.16

  78. 78.

    Chen E Proestou G Bourbeau D Wang E. Rapid up-regulation of peptide elongation factor EF-1alpha protein levels is an immediate early event during oxidative stress-induced apoptosis. Exp Cell Res (2000 ) 259(1):140–8.

    Not in our library10.1006/excr.2000.4952

  79. 79.

    Day AM Brown JD Taylor SR Rand JD Morgan BA Veal EA. Inactivation of a peroxiredoxin by hydrogen peroxide is critical for thioredoxin-mediated repair of oxidized proteins and cell survival. Mol Cell (2012 ) 45(3):398–408.

    Not in our library10.1016/j.molcel.2011.11.027

  80. 80.

    Talapatra S Wagner JD Thompson CB. Elongation factor-1 alpha is a selective regulator of growth factor withdrawal and ER stress-induced apoptosis. Cell Death Differ (2002 ) 9(8):856–61.

    Not in our library10.1038/sj.cdd.4401078

  81. 81.

    Newbery HJ Loh DH O’Donoghue JE Tomlinson VA Chau YY Boyd JA Translation elongation factor eEF1A2 is essential for post-weaning survival in mice. J Biol Chem (2007 ) 282(39):28951–9.

    Not in our library10.1074/jbc.m703962200

  82. 82.

    Chambers DM Peters J Abbott CM. The lethal mutation of the mouse wasted (wst) is a deletion that abolishes expression of a tissue-specific isoform of translation elongation factor 1alpha, encoded by the Eef1a2 gene. Proc Natl Acad Sci U S A (1998 ) 95(8):4463–8.

    Not in our library10.1073/pnas.95.8.4463

  83. 83.

    Potter M Bernstein A Lee JM. The wst gene regulates multiple forms of thymocyte apoptosis. Cell Immunol (1998 ) 188(2):111–7.

    Not in our library10.1006/cimm.1998.1346

  84. 84.

    Nakajima J Okamoto N Tohyama J Kato M Arai H Funahashi O De novo eEF1A2 mutations in patients with characteristic facial features, intellectual disability, autistic behaviors and epilepsy. Clin Genet (2015 ) 87(4):356–61.

    Not in our library10.1111/cge.12394

  85. 85.

    Ruest LB Marcotte R Wang E. Peptide elongation factor eEF1A-2/S1 expression in cultured differentiated myotubes and its protective effect against caspase-3-mediated apoptosis. J Biol Chem (2002 ) 277(7):5418–25.

    Not in our library10.1074/jbc.m110685200

  86. 86.

    Abbott CM Newbery HJ Squires CE Brownstein D Griffiths LA Soares DC eEF1A2 and neuronal degeneration. Biochem Soc Trans (2009 ) 37(Pt 6):1293–7

    Not in our library10.1042/bst0371293

  87. 87.

    Li D Wei T Abbott CM Harrich D. The unexpected roles of eukaryotic translation elongation factors in RNA virus replication and pathogenesis. Microbiol Mol Biol Rev (2013 ) 77(2):253–66.

    Not in our library10.1128/mmbr.00059-12

  88. 88.

    Cimarelli A Luban J. Translation elongation factor 1-alpha interacts specifically with the human immunodeficiency virus type 1 Gag polyprotein. J Virol (1999 ) 73(7):5388–401.

    Not in our library10.1128/jvi.73.7.5388-5401.1999

  89. 89.

    Ott DE Coren LV Johnson DG Kane BP Sowder RC Kim YD Actin-binding cellular proteins inside human immunodeficiency virus type 1. Virology (2000 ) 266(1):42–51.

    Not in our library10.1006/viro.1999.0075

  90. 90.

    Warren K Wei T Li D Qin F Warrilow D Lin MH Eukaryotic elongation factor 1 complex subunits are critical HIV-1 reverse transcription cofactors. Proc Natl Acad Sci U S A (2012 ) 109(24):9587–92.

    Not in our library10.1073/pnas.1204673109

  91. 91.

    Allouch A Cereseto A. Identification of cellular factors binding to acetylated HIV-1 integrase. Amino Acids (2011 ) 41(5):1137–45.

    Not in our library10.1007/s00726-009-0444-3

  92. 92.

    Parissi V Calmels C De Soultrait VR Caumont A Fournier M Chaignepain S Functional interactions of human immunodeficiency virus type 1 integrase with human and yeast HSP60. J Virol (2001 ) 75(23):11344–53.

    Not in our library10.1128/jvi.75.23.11344-11353.2001

  93. 93.

    Tan R Patni H Tandon P Luan L Sharma B Salhan D Nef interaction with actin compromises human podocyte actin cytoskeletal integrity. Exp Mol Pathol (2013 ) 94(1):51–7.

    Not in our library10.1016/j.yexmp.2012.06.001

  94. 94.

    Wu-Baer F Lane WS Gaynor RB. Identification of a group of cellular cofactors that stimulate the binding of RNA polymerase II and TRP-185 to human immunodeficiency virus 1 TAR RNA. J Biol Chem (1996 ) 271(8):4201–8.

    Not in our library10.1074/jbc.271.8.4201

  95. 95.

    Abbas W Dichamp I Herbein G. The HIV-1 Nef protein interacts with two components of the 40S small ribosomal subunit, the RPS10 protein and the 18S rRNA. Virol J (2012 ) 9:103.

    Not in our library10.1186/1743-422x-9-103

  96. 96.

    Xiao H Neuveut C Benkirane M Jeang KT. Interaction of the second coding exon of Tat with human EF-1 delta delineates a mechanism for HIV-1-mediated shut-off of host mRNA translation. Biochem Biophys Res Commun (1998 ) 244(2):384–9.

    Not in our library10.1006/bbrc.1998.8274

  97. 97.

    Lin WS Jiao BY Wu YL Chen WN Lin X. Hepatitis B virus X protein blocks filamentous actin bundles by interaction with eukaryotic translation elongation factor 1 alpha 1. J Med Virol (2012 ) 84(6):871–7.

    Not in our library10.1002/jmv.23283

  98. 98.

    Sikora D Greco-Stewart VS Miron P Pelchat M. The hepatitis delta virus RNA genome interacts with eEF1A1, p54(nrb), hnRNP-L, GAPDH and ASF/SF2. Virology (2009 ) 390(1):71–8.

    Not in our library10.1016/j.virol.2009.04.022

  99. 99.

    Yue J Shukla R Accardi R Zanella-Cleon I Siouda M Cros MP Cutaneous human papillomavirus type 38 E7 regulates actin cytoskeleton structure for increasing cell proliferation through CK2 and the eukaryotic elongation factor 1A. J Virol (2011 ) 85(17):8477–94.

    Not in our library10.1128/jvi.02561-10

  100. 100.

    Blackwell JL Brinton MA. Translation elongation factor-1 alpha interacts with the 3’ stem-loop region of West Nile virus genomic RNA. J Virol (1997 ) 71(9):6433–44.

    Not in our library10.1128/jvi.71.9.6433-6444.1997

  101. 101.

    Davis WG Blackwell JL Shi PY Brinton MA. Interaction between the cellular protein eEF1A and the 3’-terminal stem-loop of West Nile virus genomic RNA facilitates viral minus-strand RNA synthesis. J Virol (2007 ) 81(18):10172–87.

    Not in our library10.1128/jvi.00531-07

  102. 102.

    Carr JM Kua T Clarke JN Calvert JK Zebol JR Beard MR Reduced sphingosine kinase 1 activity in dengue virus type-2 infected cells can be mediated by the 3’ untranslated region of dengue virus type-2 RNA. J Gen Virol (2013 ) 94(Pt 11):2437–48.

    Not in our library10.1099/vir.0.055616-0

  103. 103.

    Zhang X Shi H Chen J Shi D Li C Feng L. EF1A interacting with nucleocapsid protein of transmissible gastroenteritis coronavirus and plays a role in virus replication. Vet Microbiol (2014 ) 172(3–4):443–8.

    Not in our library10.1016/j.vetmic.2014.05.034

  104. 104.
    Analysis of virion associated host proteins in vesicular stomatitis virus using a proteomics approach · 2009
    Not checked
  105. 105.

    Chung CS Chen CH Ho MY Huang CY Liao CL Chang W. Vaccinia virus proteome: identification of proteins in vaccinia virus intracellular mature virion particles. J Virol (2006 ) 80(5):2127–40.

    Not in our library10.1128/jvi.80.5.2127-2140.2006

  106. 106.

    Resch W Hixson KK Moore RJ Lipton MS Moss B. Protein composition of the vaccinia virus mature virion. Virology (2007 ) 358(1):233–47.

    Not in our library10.1016/j.virol.2006.08.025

  107. 107.

    Kattenhorn LM Mills R Wagner M Lomsadze A Makeev V Borodovsky M Identification of proteins associated with murine cytomegalovirus virions. J Virol (2004 ) 78(20):11187–97.

    Not in our library10.1128/jvi.78.20.11187-11197.2004

  108. 108.

    Varnum SM Streblow DN Monroe ME Smith P Auberry KJ Pasa-Tolic L Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome. J Virol (2004 ) 78(20):10960–6.

    Not in our library10.1128/jvi.78.23.13395.2004

  109. 109.

    Neuman BW Joseph JS Saikatendu KS Serrano P Chatterjee A Johnson MA Proteomics analysis unravels the functional repertoire of coronavirus nonstructural protein 3. J Virol (2008 ) 82(11):5279–94.

    Not in our library10.1128/jvi.02631-07

  110. 110.

    Tang H Oishi N Kaneko S Murakami S. Molecular functions and biological roles of hepatitis B virus x protein. Cancer Sci (2006 ) 97(10):977–83.

    Not in our library10.1111/j.1349-7006.2006.00299.x

  111. 111.

    Ghittoni R Accardi R Hasan U Gheit T Sylla B Tommasino M. The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes (2010 ) 40(1):1–13.

    Not in our library10.1007/s11262-009-0412-8

  112. 112.

    Chertova E Chertov O Coren LV Roser JD Trubey CM Bess JW Jr Proteomic and biochemical analysis of purified human immunodeficiency virus type 1 produced from infected monocyte-derived macrophages. J Virol (2006 ) 80(18):9039–52.

    Not in our library10.1128/jvi.01013-06

Cited by papers we hold 5

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.